Advertisement Endoscopic Duodenal Mucosal Resurfacing May Lead To Better Levels Of Metabolic Markers In Patients With T2D.

reports that researchers found, “in a first-in-human, single-arm study, 39 patients in Chile with type 2 diabetes who underwent endoscopic duodenal mucosal resurfacing, known as the Revita procedure (Fractyl), had better levels of metabolic markers at 6 months with no serious lasting adverse effects.” The findings were presented at a medical conference. According to Medscape, should these findings be “reproduced in further, larger studies with a sham control arm, clinicians may someday be able to offer diabetic patients this minimally invasive treatment – which seems to provide potential improvements in diabetes similar to those seen with gastric-bypass surgery.”